Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION (Tables)

v3.19.3.a.u2
SEGMENT INFORMATION (Tables)
12 Months Ended
Oct. 31, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

 

Year Ended October 31,

 

2019

 

2018

Net loss:

 

 

 

 

 

Cancer diagnostics

$

(5,196,471)

 

$

(5,920,457)

Cancer therapeutics

 

(5,752,318)

 

 

(7,073,322)

Patent licensing

 

(869,863)

 

 

(1,249,305)

Total

$

(11,818,652)

 

$

(14,243,084)

 

 

 

 

 

 

Total operating costs and expenses

$

12,140,005

 

$

15,401,558

Less non-cash share-based compensation

 

(5,713,746)

 

 

(8,895,614)

Operating costs and expenses excluding non-cash
   share-based compensation

$

6,426,259

 

$

6,505,944

 

 

 

 

 

 

Operating costs and expenses excluding non-cash

   share based compensation expense:

 

 

 

 

 

Cancer diagnostics

$

2,689,761

 

$

2,431,810

Cancer therapeutics

 

2,670,482

 

 

2,120,614

Patent licensing

 

1,066,016

 

 

1,953,520

Total

$

6,426,259

 

$

6,505,944

 

October 31,

 

2019

 

2018

Total assets:

 

 

 

 

 

Cancer diagnostics

$

2,921,784

 

$

2,545,803

Cancer therapeutics

 

2,872,341

 

 

2,157,359

Patent licensing

 

499,568

 

 

1,745,380

Total

$

6,293,693

 

$

6,448,542